Willard Dere

Dr. Willard H.
Dere, MD, is a Chief Medical Officer at Angitia Biopharmaceuticals Guangzhou Ltd., a Chairman at Metagenomi Therapeutics, Inc., an Independent Director at Seres Therapeutics, Inc. and an Independent Director at BioMarin Pharmaceutical, Inc. He is on the Board of Directors at Seres Therapeutics, Inc., BioMarin Pharmaceutical, Inc. and Peel Therapeutics, Inc. Dr. Dere was previously employed as an Independent Director by Mersana Therapeutics, Inc., an Independent Director by OCERA Therapeutics LLC, an Independent Director by Radius Health, Inc., a Professor-Emeritus by The University of Utah Health Sciences Center, an International Chief Medical Officer by Amgen, Inc., a Vice President-Endocrine & Bone by Eli Lilly & Co., and an Associate Professor by The Indiana University School of Medicine.
He also served on the board at Metagenomi Technologies LLC, Clinical & Translational Science Institute and Center for Genomic Medicine Massachusetts General Hospital.
He received his undergraduate degree from the University of California, Davis and a doctorate degree from the University of California, Davis.